Empery Asset Management, LP is an SEC-registered investment adviser based in New York City, NY that reports managing 4 hedge funds on Form ADV. It reports $262.5 million in regulatory assets under management. Its private funds, of all types, hold $262.5 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +11.3% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +11.3% from Q1 2026 to Q2 2026, compared with +9.5% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $262.5 millionForm ADV Item 5.F
- Gross assets of private funds
- $262.5 millionAll private fund types, Form ADV
- Hedge funds managed
- 44 private funds in total
- Employees
- 6Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 148180
- Latest Form ADV
- 03/31/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +9.0% | +14.8% |
| Q1 2026 | +2.1% | -4.6% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Jun 30, 2026
All 32 share positions ($86,479,405) reported by Empery Asset Management, LP on Form 13F for the quarter ended Jun 30, 2026, filed Aug 11, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| X4 Pharmaceuticals Inc | $32,365,860 | 37.43% | 6,930,591 | -22.51% |
| Empery Digital Inc | $10,432,028 | 12.06% | 2,930,345 | Unchanged |
| Nervgen Pharma Corp | $8,240,000 | 9.53% | 4,000,000 | New |
| Precision Biosciences Inc | $6,100,091 | 7.05% | 776,093 | -60.58% |
| Clene Inc | $5,641,254 | 6.52% | 916,532 | New |
| Annovis Bio Inc | $4,466,745 | 5.17% | 2,401,476 | New |
| Lantern Pharma Inc | $3,513,930 | 4.06% | 842,669 | New |
| Amc Entmt Hldgs Inc | $3,256,682 | 3.77% | 1,714,043 | New |
| Tenaya Therapeutics Inc | $2,855,228 | 3.30% | 3,863,115 | -9.89% |
| One And One Green Technologi | $1,538,646 | 1.78% | 761,706 | New |
| Cyngn Inc | $1,288,612 | 1.49% | 927,059 | -3.21% |
| Venu Hldg Corp | $1,164,097 | 1.35% | 512,818 | -49.11% |
| Greenland Energy Co | $850,000 | 0.98% | 1,000,000 | New |
| Ur-energy Inc | $843,385 | 0.98% | 620,136 | Unchanged |
| Satellos Bioscience Inc | $832,703 | 0.96% | 107,100 | -53.46% |
| Jaguar Uranium Corp | $814,125 | 0.94% | 487,500 | Unchanged |
| Cellectar Biosciences Inc | $527,102 | 0.61% | 189,605 | New |
| Scynexis Inc | $514,656 | 0.60% | 126,451 | New |
| Rein Therapeutics Inc | $385,667 | 0.45% | 370,834 | New |
| BTC Digital LTD | $288,912 | 0.33% | 350,877 | New |
| Briacell Therapeutics Corp | $267,000 | 0.31% | 300,000 | Unchanged |
| Maris Tech LTD | $58,032 | 0.07% | 297,600 | Unchanged |
| Parazero Technologies LTD | $55,338 | 0.06% | 113,771 | -59.68% |
| Duke Robotics Corp | $45,150 | 0.05% | 35,000 | New |
| Nutriband Inc | $40,218 | 0.05% | 40,218 | Unchanged |
| Renatus Tactical Acquis | $38,000 | 0.04% | 50,000 | Unchanged |
| Spectral Ai Inc | $18,501 | 0.02% | 33,336 | Unchanged |
| Nexera Technologies LTD | $10,421 | 0.01% | 360,577 | Unchanged |
| Cea Industries Inc | $9,250 | 0.01% | 500,000 | Unchanged |
| Fgi Industries LTD | $7,973 | 0.01% | 83,928 | Unchanged |
| Neurosense Therapeutics LTD | $6,325 | 0.01% | 100,402 | Unchanged |
| Nexgel Inc | $3,474 | 0.00% | 90,000 | Unchanged |
Changes since Mar 31, 2026
Comparing the share counts in the two quarter-end filings: 12 new positions, 12 sold out, 0 increased, 7 reduced and 13 unchanged.
New positions
| Stock | Value | Shares |
|---|---|---|
| Nervgen Pharma Corp | $8,240,000 | 4,000,000 |
| Clene Inc | $5,641,254 | 916,532 |
| Annovis Bio Inc | $4,466,745 | 2,401,476 |
| Lantern Pharma Inc | $3,513,930 | 842,669 |
| Amc Entmt Hldgs Inc | $3,256,682 | 1,714,043 |
| One And One Green Technologi | $1,538,646 | 761,706 |
| Greenland Energy Co | $850,000 | 1,000,000 |
| Cellectar Biosciences Inc | $527,102 | 189,605 |
| Scynexis Inc | $514,656 | 126,451 |
| Rein Therapeutics Inc | $385,667 | 370,834 |
| BTC Digital LTD | $288,912 | 350,877 |
| Duke Robotics Corp | $45,150 | 35,000 |
Sold out
| Stock | Value at Mar 31, 2026 | Shares held then |
|---|---|---|
| Imperial Pete Inc | $3,756,321 | 877,645 |
| Big SKY Indl Inc | $1,695,566 | 1,917,844 |
| Scynexis Inc | $1,694,272 | 1,847,826 |
| Critical Metals Corp | $1,048,390 | 132,039 |
| Promis Neurosciences Inc | $766,483 | 60,353 |
| Super League Enterprise Inc | $491,793 | 132,917 |
| Talphera Inc | $441,030 | 590,481 |
| Benitec Biopharma Inc | $324,186 | 30,440 |
| Abits Group Inc | $266,052 | 172,761 |
| Nasus Pharma LTD | $101,683 | 45,803 |
| Briacell Therapeutics Corp | $93,324 | 666,600 |
| Medicus Pharma LTD | $11,494 | 12,100 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| X4 Pharmaceuticals Inc | -2,013,527 | -22.51% | $32,365,860 | 6,930,591 |
| Precision Biosciences Inc | -1,192,786 | -60.58% | $6,100,091 | 776,093 |
| Venu Hldg Corp | -494,911 | -49.11% | $1,164,097 | 512,818 |
| Satellos Bioscience Inc | -123,000 | -53.45% | $832,703 | 107,100 |
| Tenaya Therapeutics Inc | -423,818 | -9.89% | $2,855,228 | 3,863,115 |
| Parazero Technologies LTD | -168,428 | -59.68% | $55,338 | 113,771 |
| Cyngn Inc | -30,725 | -3.21% | $1,288,612 | 927,059 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Annovis Bio, Inc. | 13G amendment | 4.99% | 2,241,537 | Oct 15, 2026 | SEC.gov ↗ |
| Femasys Inc. | 13G | 5.6% | 468,750 | Oct 15, 2026 | SEC.gov ↗ |
| Dyadic International Inc. | 13G | 8.35% | 3,346,275 | Oct 15, 2026 | SEC.gov ↗ |
| Lantern Pharma Inc. | 13G amendment | 4.99% | 755,891 | Oct 13, 2026 | SEC.gov ↗ |
| Clene Inc. | 13G amendment | 1.56% | 221,660 | Oct 13, 2026 | SEC.gov ↗ |
| Outlook Therapeutics, Inc. | 13G | 8.73% | 21,247,856 | Oct 13, 2026 | SEC.gov ↗ |
| Empery Digital Inc. | 13D amendment | 17.15% | 4,830,345 | Sep 3, 2026 | SEC.gov ↗ |
| Cellectar Biosciences, Inc. | 13G | 9.99% | 864,090 | Aug 4, 2026 | SEC.gov ↗ |
| Abits Group Inc. | 13G amendment | 0% | 0 | Jul 29, 2026 | SEC.gov ↗ |
| Super League Enterprise, Inc. | 13G amendment | 4.99% | 85,909 | Jul 29, 2026 | SEC.gov ↗ |
| Precision BioSciences, Inc. | 13G amendment | 4.99% | 1,314,393 | Jul 29, 2026 | SEC.gov ↗ |
| Cyngn Inc. | 13G | 9.99% | 1,404,049 | Apr 22, 2026 | SEC.gov ↗ |
| Imperial Petroleum Inc. | 13G amendment | 4.99% | 2,298,892 | Apr 15, 2026 | SEC.gov ↗ |
| Robin Energy Ltd. | 13G amendment | 0% | 0 | Apr 15, 2026 | SEC.gov ↗ |
| Immuneering Corp | 13G amendment | 4.99% | 3,250,775 | Jan 15, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Oct 21, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 19 companies. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (5)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (4)
As reported in the adviser's Form ADV filed Mar 29, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures